Aurobindo Pharma Limited has informed the Exchange regarding a press release dated November 22, 2023, titled "Press Release - Evive Biotech and Acrotech Biopharma Announce FDA Approval of Ryzneuta for Chemotherapy-Induced Neutropenia (CIN)".
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated November 22, 2023, titled "Press Release - Evive Biotech and Acrotech Biopharma Announce FDA Approval of Ryzneuta for Chemotherapy-Induced Neutropenia (CIN)".